Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.

Erityisesti laatu viagra tästä kaupasta voi taata henkilökohtaisesti cialis Paras laatu kehotan Teitä miellyttää.

Oklahoma board of nursing crna inclusionary formulary

CRNA Inclusionary Formulary
To be granted authority to select, order, obtain and administer drugs, Certified Registered Nurse Anesthetists
(CRNAs) must hold a current Registered Nurse license, be recognized as a CRNA in Oklahoma and meet the
continuing education requirements noted in the Rules of the Oklahoma Board of Nursing, specifically 485:10-18-2.
Pursuant to 59 O.S. § 567.3a.10 [Oklahoma Nursing Practice Act], a Formulary Advisory Council has been
established to develop and submit to the Board recommendations for an inclusionary formulary.
The following Board-approved CRNA Inclusionary Formulary lists drugs that may be ordered, selected, obtained or
administered during the perioperative and periobstetrical periods by CRNAs who have been granted authority by
the Board to select, order, obtain, and administer drugs.

4:00

Antihistamine Drugs
First Generation Antihistamines
Diphenhydramine Hydrochloride
Promethazine Hydrochloride (see also 28:24.92 and 28:16.08.24) [CAUTION:BE
AWARE OF PEDIATRIC RESTRICTIONS. CAUTION WITH IV USE.]

12:00 Autonomic Agents
Parasympathomimetic (Cholinergic) Agents Atropine Glycopyrrolate Ipratropium Bromide Scopolomine 12:12.08.04 Non-selective β-Adrenergic Agonists 12:12.08.08 Selective β1-Adrenergic Agonists 12:12.08.12 Selective β2-Adrenergic Agonists Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm Sympatholytic (Adrenergic Blocking) Agents 12:16.04.04 Non-selective α-Adrenergic Blocking Agents Skeletal Muscle Relaxants (all intravenous future new drugs approved) 12:20.08 Direct-acting Skeletal Muscle Relaxants Blood Derivatives

Blood and Blood Components (not in AHFS)

20:00

Blood Formation and Coagulation
Antihemorrhagic Agents 20:28.08 Antiheparin Agents
24:00 Cardiovascular Drugs

Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm 24:28.92 Calcium-Channel Blocking Agents, Miscellaneous Renin-Angiotensin-Aldosterone System Inhibitors 24:32.04 Angiotensin-Converting Enzyme Inhibitors Central Nervous System Agents
28:04
General Anesthetics (all in this class approved including future new drugs) 28:04.92 General Anesthetics, Miscellaneous 28:08.04 Nonsteroidal Antiflammatory Agents 28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents 28:08.08 Opiate Agonists (all in this class approved including future new drugs) [NOTE: BE AWARE OF PEDIATRIC CAUTION]***
Hydrocodone Hydromorphone Levorphanol* Meperidine Morphine Remifentanil* Sufentanil Citrate Tramadol 28:08.12 Opiate Partial Agonists (all in this class approved including future new drugs) 28:08.92 Analgesics and Antipyretic, Miscellaneous Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm Opiate Antagonists (all in this class approved including future new drugs) Nalmefene* Naloxone Naltrexone Ethotoin Fosphenytoin Phenytoin 28:12.92 Anticonvulsants, Miscellaneous Anorexigenic Agents and Respiratory and CNS Stimulants Anxiolytics, Sedatives, and Hypnotics 28:24.04 Barbiturates* (all in this class approved including future new drugs) 28:24.08 Benzodiazepines (all in this class approved including future new drugs) Diazepam Lorazepam Midazolam Temazepam* 28:24.92 Anxiolytics, Sedatives and Hypnotics; Miscellaneous [NOTE: Adult dosage not to exceed a total dose of 1.25 mg;
Pediatric dosage not to exceed a one-time dose of 10 mcg/kg.]
Central Nervous System Agents, Miscellaneous Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm Diagnostic Agents
Electrolytic, Caloric, and Water Balance
40:08
Dextran 70
Dextran75 (not in AHFS) [CAUTION: POTENTIAL COMPLICATION OF ANAPHYLACTIC
REACTION TO DEXTRAN 75]
Electrolyte Solutions*
Hetastarch [CAUTION: POTENTIAL COMPLICATION OF ANAPHYLACTIC REACTION TO
HETASTARCH IN PATIENTS ALLERGIC TO LATEX.]
Salt and Sugar Substitutes (not in AHFS) Irrigating Solutions* Sterile water for injection* Respiratory Tract Agents (all in this class approved including future new drugs)
48:08
Benzonatate* Codeine Dextromethorphan Hydrocodone Mucolytic Agents Acetylcysteine (see also 92:12) Eye, Ear, Nose, and Throat (EENT) Preparations
52:16
Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm Gastrointestinal Drugs
56:04
Aluminum Carbonate Aluminum Hydroxide Aluminum Phosphate Antacids Calcium Carbonate Charcoal, Activated Dihydroxyaluminum Aminoacetate Dihydroxyaluminum Sodium Carbonate Magaldrate Magnesium Carbonate Magnesium Hydroxide Magnesium Oxide Magnesium Trisilicate Sodium Bicarbonate Hormones and Synthetic Substitutes
68:04
Adrenals (all in this class approved including future new drugs) Beclomethasone Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm Betamethasone Cortisone Acetate Dexamethasone Fludrocortisone Flunisolide* Hydrocortisone Methlyprednisolone Prednisolone Prednisone Triamcinolone Local Anesthetics (all in this class approved including future new drugs) Articaine
Bupivacaine
Chloroprocaine
Lidocaine
Mepivacaine
Prilocaine
Procaine (not in AHFS)
Ropivacaine (not in AHFS)
Tetracaine
Oxytocics
Carboprost Tromethamine*
Dinoprostone
Ergonovine/Methergonovine
Oxytocin
Sodium Chloride 20% Injection
Urea 40-50% Injection
Skin and Mucous Membrane Agents
84:08
Antipruritics and Local Anesthetics (all in this class approved including future new drugs) Benzocaine* Dibucaine* Doxepin* Ethyl Chloride* Phenazopyridine* Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm Smooth Muscle Relaxants
86:16
Respiratory Smooth Muscle Relaxants Aminophylline Theophyllines Vitamins*
Miscellaneous Therapeutic Agents
92:12 Antidotes

[NOTE: ACLS Algorithm medications are listed according to the classification system in the AHFS Drug
Information resource.]

Regulatory Authority:
59 O.S. §567.4b. C.
Reference:
American Hospital Formulary Service®. AHFS Drug Information (2013). Published by Authority of the Board of
the American Society of Health-System Pharmacists®, Bethesda, MD.
*Omitted from the print version of AHFS Drug Information because of space limitations, as stated by the publisher.
May view the AHFS Drug Information website:
**Reference for Ketamine:
*** Reference for Codeine precautions
Board Reviewed w/o Revision: 1/28/99; 5/23/06 Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm

Source: http://www.state.ok.us/nursing/prac-crnafrm.pdf

Aggiornam (17-32)

AGGIORNAMENTI TERAPIA FARMACOLOGICA DELL’ASMA BRONCHIALE CRONICO Premessa 3. Obiettivi del trattamento dell’asma a lungo In questi ultimi anni si sono registrati indiscutibi-li progressi nel trattamento dell’asma bronchiale eI principali obiettivi del trattamento dell’asmaciò grazie ad una ampia e continua diffusione, e con-seguente attuazione, di corrette linee di interve

Microsoft word - 0412-1- full article for test statin use and risk of diabetes mellitus

Statin use in postmenopausal women increases risk of type 2 diabetes, but benefits may still outweigh risks A recent study has found that that the use of statins in postmenopausal women is associated with an increased risk of diabetes mel itus (DM). However, further studies are warranted, and some experts say that the benefits stil outweigh the risks. The study set out to evaluate whether

Copyright © 2010-2014 Medical Pdf Articles